1[1]Kauser F,Khan AA,Hussain MA,et al.The cag pathogenicity island of Helicobacter pylori is disrupted in the majority of patient isolates from different human populations.J Clin Microbiol 2004;42:5302-5308.
2[2]Liu J,Xu GM,Li ZS,et al.The characteristic structure and classified valee of cag pathogenicity island in Chinese Helicobacter pylori strains.Chin J Dig Dis 2002;3:79-84.
4[4]de Jonge R,Kuipers EJ,Langeveld SC,et al.The Helicobacter pylori plasticity region locus jhp0947-jhp0949 is associated with duodenal ulcer disease and interleukin-12 production in monocyte cells.FEMS Immunol Med Microbiol 2004;41:161-167.
5[5]Lu CC,Sheu BS,Chen TW,et al.Host TNF-alpha-1031 and -863promoter single nucleotide polymorphisms determine the risk of benign ulceration after H.pylori infection.Am J Gastroenterol 2005;100:1274-1282.
6[6]Rosenstock SJ,Jorgensen T,Bonnevie O,et al.Does Helicobacter pylori infection explain all socio-economic differences in peptic ulcer incidence? Genetic and psychosocial markers for incident peptic ulcer disease in a large cohort of Danish adults.Scand J Gastroenterol 2004;39:823-829.
7[7]Ford A,Delaney B,Forman D,et al.Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients.Cochrane Database Syst Rev 2004;(4):CD003840.
9[9]Gisbert JP,Khorrami S,Carballo F,et al.H.pylori eradication therapy vs.antisecretory non-eradication therapy (with or without longterm maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.Cochrane Database Syst Rev 2004;(2):CD004062.
1Juntaro Matsuzaki,Hidekazu Suzuki,Toshihiro Nishizawa,et al.Effica-cy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First-and Second-Line Therapies [ J ].Antimicrobial Agents and Chemotherapy,2012,56(3):1643-1645.
